Alector Quote - ALEC

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

3.675

Bid

3.66

Offer

3.69

Volume

328,504

3.49 Day's Range 3.675

3.49 52 Week Range 8.90

Market Cap

359.902M

Previous Close

3.635

Open

3.65

Last Trade

3.662

Last Trade Time

03:15:42

Financial Volume

US$ 1,169,096

VWAP

3.5588

Average Volume (3m)

596,452

Shares Outstanding

97,932,605

Dividend Yield

PE Ratio

-2.64

Earnings Per Share (EPS)

-1.33

Revenue

97.06M

Net Profit

-130.39M

Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to... Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline product inlcude AL001, AL002, AL003, and AL101. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.alector.com

Headquarters

Wilmington, Delaware, USA

Founded

Alector Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ALEC. The last closing price for Alector was US$3.64. Over the last year, Alector shares have traded in a share price range of US$ 3.49 to US$ 8.90.

Alector currently has 97,932,605 shares in issue. The market capitalisation of Alector is US$355.99 million. Alector has a price to earnings ratio (PE ratio) of -2.64.

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

--Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.485	-28.7790697674	5.16	5.16	3.49	774916	3.95938892	CS
4	-1.025	-21.8085106383	4.7	6.14	3.49	736564	4.92511361	CS
12	-1.625	-30.6603773585	5.3	6.37	3.49	596452	5.04971081	CS
26	-1.705	-31.6914498141	5.38	6.78	3.49	603846	5.10919485	CS
52	-1.125	-23.4375	4.8	8.9	3.49	623745	5.73388177	CS
156	-17.6884	-82.7976820169	21.3634	24.005	3.49	618156	8.64900111	CS
260	-12.315	-77.0168855535	15.99	45	3.49	677039	15.03918715	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WORXSCWorx Corporation	US$ 1.892 (93.06%)	105.42M
CRNCCerence Inc	US$ 5.17 (83.33%)	32.73M
BDRXBiodexa Pharmaceuticals PLC	US$ 6.13 (59.22%)	3.73M
IBGInnovation Beverage Group Limited	US$ 1.1309 (42.93%)	6.83M
SPAISafe Pro Group Inc	US$ 4.4871 (40.22%)	38.45M
PYXSPyxis Oncology Inc	US$ 2.055 (-46.20%)	9.59M
GLXGGalaxy Payroll Group Ltd	US$ 2.20 (-43.73%)	507.51k
KURAKura Oncology Inc	US$ 9.99 (-37.21%)	7.54M
BLRXBioLineRx Ltd	US$ 0.3571 (-34.50%)	5.72M
SHOTWSafety Shot Inc	US$ 0.1001 (-33.27%)	2.5k
CDTConduit Pharmaceuticals Inc	US$ 0.1109 (20.15%)	490.48M
NVDANVIDIA Corporation	US$ 143.81 (-1.43%)	205.05M
AKTSAkoustis Technologies Inc	US$ 0.1014 (16.42%)	183.54M
ELABElevai Labs Inc	US$ 0.0201 (-6.07%)	150.44M
WORXSCWorx Corporation	US$ 1.892 (93.06%)	105.42M